197 related articles for article (PubMed ID: 9440488)
1. Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease.
Jovinge S; Hamsten A; Tornvall P; Proudler A; Båvenholm P; Ericsson CG; Godsland I; de Faire U; Nilsson J
Metabolism; 1998 Jan; 47(1):113-8. PubMed ID: 9440488
[TBL] [Abstract][Full Text] [Related]
2. Plasma tumor necrosis factor alpha levels and insulin sensitivity in hypertensive subjects.
Sheu WHH ; Lee WJ; Chang RL; Chen YT
Clin Exp Hypertens; 2000 Aug; 22(6):595-606. PubMed ID: 10972164
[TBL] [Abstract][Full Text] [Related]
3. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome.
Grundy SM
Am J Cardiol; 1998 Feb; 81(4A):18B-25B. PubMed ID: 9526809
[TBL] [Abstract][Full Text] [Related]
4. Association of insulin and insulin propeptides with an atherogenic lipoprotein phenotype.
Båvenholm P; Karpe F; Proudler A; Tornvall P; Crook D; Hamsten A
Metabolism; 1995 Nov; 44(11):1481-8. PubMed ID: 7476338
[TBL] [Abstract][Full Text] [Related]
5. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial.
Jonkers IJ; Mohrschladt MF; Westendorp RG; van der Laarse A; Smelt AH
Am J Med; 2002 Mar; 112(4):275-80. PubMed ID: 11893366
[TBL] [Abstract][Full Text] [Related]
6. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
Goa KL; Barradell LB; Plosker GL
Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
[TBL] [Abstract][Full Text] [Related]
7. Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
de Faire U; Ericsson CG; Hamsten A; Nilsson J
Drugs Exp Clin Res; 1995; 21(3):105-24. PubMed ID: 7555614
[TBL] [Abstract][Full Text] [Related]
8. Relationships of insulin and intact and split proinsulin to haemostatic function in young men with and without coronary artery disease.
Båvenholm P; Proudler A; Silveira A; Crook D; Blombäck M; de Faire U; Hamsten A
Thromb Haemost; 1995 Apr; 73(4):568-75. PubMed ID: 7495060
[TBL] [Abstract][Full Text] [Related]
9. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Fruchart JC; Duriez P
Drugs Today (Barc); 2006 Jan; 42(1):39-64. PubMed ID: 16511610
[TBL] [Abstract][Full Text] [Related]
10. Triglyceride as a risk factor for coronary artery disease.
Gotto AM
Am J Cardiol; 1998 Nov; 82(9A):22Q-25Q. PubMed ID: 9819100
[TBL] [Abstract][Full Text] [Related]
11. Relationship between lipoprotein levels and in vivo insulin action in normal young white men.
Garg A; Helderman JH; Koffler M; Ayuso R; Rosenstock J; Raskin P
Metabolism; 1988 Oct; 37(10):982-7. PubMed ID: 3050370
[TBL] [Abstract][Full Text] [Related]
12. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.
Ericsson CG; Hamsten A; Nilsson J; Grip L; Svane B; de Faire U
Lancet; 1996 Mar; 347(9005):849-53. PubMed ID: 8622389
[TBL] [Abstract][Full Text] [Related]
13. Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry.
Klempfner R; Erez A; Sagit BZ; Goldenberg I; Fisman E; Kopel E; Shlomo N; Israel A; Tenenbaum A
Circ Cardiovasc Qual Outcomes; 2016 Mar; 9(2):100-8. PubMed ID: 26957517
[TBL] [Abstract][Full Text] [Related]
14. Evidence for an independent relationship between plasma insulin and concentration of high density lipoprotein cholesterol and triglyceride.
Zavaroni I; Dall'Aglio E; Alpi O; Bruschi F; Bonora E; Pezzarossa A; Butturini U
Atherosclerosis; 1985 Jun; 55(3):259-66. PubMed ID: 3893447
[TBL] [Abstract][Full Text] [Related]
15. Bezafibrate reduces blood glucose in type 2 diabetes mellitus.
Ogawa S; Takeuchi K; Sugimura K; Fukuda M; Lee R; Ito S; Sato T
Metabolism; 2000 Mar; 49(3):331-4. PubMed ID: 10726910
[TBL] [Abstract][Full Text] [Related]
16. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man.
Kesäniemi YA; Grundy SM
JAMA; 1984 May; 251(17):2241-6. PubMed ID: 6368883
[TBL] [Abstract][Full Text] [Related]
17. Triglycerides and coronary risk.
Gaziano JM
Curr Cardiol Rep; 1999 Jul; 1(2):125-30. PubMed ID: 10980831
[TBL] [Abstract][Full Text] [Related]
18. Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment.
Ruotolo G; Båvenholm P; Brismar K; Eféndic S; Ericsson CG; de Faire U; Nilsson J; Hamsten A
J Am Coll Cardiol; 2000 Mar; 35(3):647-54. PubMed ID: 10716467
[TBL] [Abstract][Full Text] [Related]
19. VLDL triglycerides inhibit HDL-associated paraoxonase 1 (PON1) activity: in vitro and in vivo studies.
Rosenblat M; Ward S; Volkova N; Hayek T; Aviram M
Biofactors; 2012; 38(4):292-9. PubMed ID: 22674772
[TBL] [Abstract][Full Text] [Related]
20. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
